Clinical Trials in Portugal

• A randomized study of XEN1101 versus placebo in Primary Generalised Tonic Clonic Seizures (X-ACKT) Recruiting
  2022-502286-16-00 Phase III Primary Generalized Tonic-Clonic Seizures Xenon Pharmaceuticals Inc.
• A study to test whether different doses of BI 764532 help people with small cell lung cancer or other neuroendocrine cancers Recruiting
  2023-504247-13-00 Phase II Small Cell Lung Cancer Boehringer Ingelheim International GmbH
• A Study of Zanubrutinib Versus Lenalidomide in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (MAHOGANY) Recruiting
  2022-502548-12-00 Phase III marginal zone lymphoma BeOne Medicines AG
• Clairleaf TM: A study to test long-term treatment with BI 1291583 in people with bronchiectasis who took part in a previous study with this … Recruiting
  2023-503290-38-00 Phase II Bronchiectasis Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH; Boehr…
• Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting
  2022-500273-14-00 Phase II/III Atherosclerotic cardiovascular disease in patients with ESKD CSL Behring LLC
• Phase III clinical trial of ABCB5+ MSCs for the treatment of EB Recruiting
  2022-500266-10-00 Phase III Recessive Dystrophic Epidermolysis Bullosa(RDEB) and Junctio… Rheacell GmbH & Co. KG
• A Phase 3b study to learn more about the safety and tolerability of ivosidenib in combination with azacitidine in adult patients newly diagn… Recruiting
  2022-501709-11-00 Phase III Isocitrate deshydrogenase1 mutation-positive (IDH1m) acute m… Servier Affaires Medicales
• Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-2) Recruiting
  2022-500700-22-00 Phase III Active Systemic Lupus Erythematosus (SLE) Bristol-Myers Squibb Services Unlimited Company
• A Phase 3, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Contezolid Acefosamil and Contezolid Compared … Recruiting
  2022-500257-16-00 Phase III Diabetic Foot Infections Micurx Pharmaceuticals Inc.
• This study is to find out the safety and effectiveness of Epcoritamab together with R-CHOP (rituximab, cyclophosphamide, doxorubicin HCL, vi… Recruiting
  2023-505277-32-00 Phase III Diffuse Large B-Cell Lymphoma (DLBCL) AbbVie Deutschland GmbH & Co. KG
• AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF MIGALASTAT HCL IN SUBJECTS WITH FABRY DISEASE AND AMENABLE GLA VARIANTS A… Recruiting
  2022-500488-10-00 Phase III Fabry Disease and Amenable GLA Variants and Severe Renal Imp… Amicus Therapeutics Inc.
• Treatment of infants under one year with acute lymphoblastic leukemia according to the Interfant-21 protocol Recruiting
  2022-502503-30-00 Phase III Acute lymphoblastic leukemia Princess Maxima Center For Pediatric Oncology
• A Phase 3 Study to Investigate the Efficacy and Safety of Brepocitinib in Adults with Dermatomyositis Recruiting
  2022-500367-12-00 Phase III Dermatomyositis Priovant Therapeutics Inc.
• Long-Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinica… Recruiting
  2023-506548-18-00 Phase II/III Dermatitis atopic Sanofi-Aventis Recherche & Developpement
• A research study to evaluate the safety and effectiveness of Zilovertamab Vedotin with or without Nemtabrutinib in adults with B-cell Malign… Recruiting
  2022-501374-19-00 Phase II Aggressive and Indolent B-cell Malignancies (mantle cell lym… Merck Sharp & Dohme LLC
• First in human study of BAY2927088 in participants who have advanced non-small cell lung cancer (NSCLC) with mutations in the genes of epide… Recruiting
  2023-503795-24-00 Phase I (FiH) Avanced Non-Small Cell Lung Cancer Bayer AG
• Phase 3 Trial of TAK-330 for Reversal of Direct Oral Factor Xa Inhibitor-induced Anticoagulation Recruiting
  2022-503012-16-00 Phase III Patients on treatment with Factor Xa Inhibitor needing for a… Takeda Development Center Americas Inc.
• A Phase 1/2/3 Study of UX701 Gene Therapy in Adults with Wilson Disease”. Recruiting
  2022-502873-40-00 Phase I (FiH) Wilson disease Ultragenyx Pharmaceutical Inc.
• A PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX (GAVE) COMPARED TO OBINUTUZU… Recruiting
  2023-506414-46-00 Phase III High risk patients defined as having at least one of the fol… University Of Cologne
• A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participan… Recruiting
  2023-505749-14-00 Phase III c-Met overexpressing EGFR wildtype non-squamous non-small ce… AbbVie Deutschland GmbH & Co. KG
• A Phase 2 Study to assess the efficacy and safety of 2 dosage regimens of oral fidrisertib (IPN60130) for the treatment of fibrodysplasia os… Recruiting
  2024-511469-13-00 Phase II Fibrodysplasia Ossificans Progressiva Clementia Pharmaceuticals Inc. An Ipsen Company
• Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis Recruiting
  2024-511686-11-00 Phase III Multiple Sclerosis in pediatric patients Novartis Pharma AG
• A Long-term Follow-up Study of Sotatercept for PAH Treatment Recruiting
  2023-509138-21-00 Phase III Pulmonary Arterial Hypertension (PAH) Acceleron Pharma Inc.
• Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma… Recruiting
  2023-508922-83-00 Phase II/III Advanced Non-Small Cell Lung Cancer Mirati Therapeutics Inc.

Showing 121–144 of 875 trials